Global /United States /Healthcare /Drug Manufacturers - General /ABEO

Abeona Therapeutics Inc.

ABEO

• NASDAQ: ABEO • Delayed

5.34USD -0.5%

As of 13 June 2026, Abeona Therapeutics Inc. has a market cap of $303.47M USD, ranking #18517 globally and #3092 in the United States. It ranks #1673 in the Healthcare sector, and #607 in the Drug Manufacturers - General industry.

Global Rank

18517

Country Rank

3092

Sector Rank

1673

Industry Rank

607

Key Stats

Market Cap

$303.47MUSD

Enterprise Value

$137.03MUSD

Revenue (TTM)

$5.82MUSD

EBITDA (TTM)

-$86.9MUSD

Net Income (TTM)

$71.18MUSD

Profit Margin

1K%

PE Ratio

5.3

PS Ratio

52.1

PB Ratio

1.9

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Vishwas Seshadri open_in_new

Employees

226

Founded

1974

IPO

19 Sep 1980

Website

abeonatherapeutics.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.5%	-5.2%	24%	10%	1%	1.2%	-0.3%	74%	-87%

News

ABEO Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ABEO Abeona Therapeutics Inc ISIN: US00289Y2063 Shares Out.: Shares Outstanding: 56.995M¹ Shares Float: 50.241M² TV: TradingView: NASDAQ: ABEO SA: Stock Analysis: NASDAQ: ABEO YF: Yahoo Finance: ABEO GF: Google Finance: NASDAQ: ABEO NQ: NASDAQ: ABEO BA: Barron's: ABEO MS: Morningstar: XNAS: ABEO	5.34 USD	TV: TradingView: NASDAQ: ABEO SA: Stock Analysis: NASDAQ: ABEO YF: Yahoo Finance: ABEO GF: Google Finance: NASDAQ: ABEO NQ: NASDAQ: ABEO BA: Barron's: ABEO MS: Morningstar: XNAS: ABEO
London Stock Exchange (LSE / LON) MIC: XLON	0H7R Abeona Therapeutics Inc ISIN: US00289Y2063 TV: TradingView: LSE: 0H7R SA: Stock Analysis: LON: 0H7R YF: Yahoo Finance: 0H7R.L GF: Google Finance: LON: 0H7R BA: Barron's: 0H7R MS: Morningstar: XLON: 0H7R	5.36 USD	TV: TradingView: LSE: 0H7R SA: Stock Analysis: LON: 0H7R YF: Yahoo Finance: 0H7R.L GF: Google Finance: LON: 0H7R BA: Barron's: 0H7R MS: Morningstar: XLON: 0H7R

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 251K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 180K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 119K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 90K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 49K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 39K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 106K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 95K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 90K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 60K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 36K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 36K%	14.6	United Kingdom

chevron_leftBack